TY  - CHAP
M1  - Book, Section
TI  - Personalized Pulmonary Medicine
A1  - Raby, Benjamin A.
A1  - Tantisira, Kelan G.
A2  - Grippi, Michael A.
A2  - Elias, Jack A.
A2  - Fishman, Jay A.
A2  - Kotloff, Robert M.
A2  - Pack, Allan I.
A2  - Senior, Robert M.
A2  - Siegel, Mark D.
PY  - 2015
T2  - Fishman's Pulmonary Diseases and Disorders, 5e
AB  - Since  the  first  draft  sequences  of  the  human  genome  were  completed  in  2001,1,2  medical  research  has  increasingly  focused  on  the  utilization  of  genetic  and  genomic  profiling  in  the  prediction  of  disease  susceptibility  and  natural  history,  as  well  as  drug  response  and  drug  development.  Personalized  medicine  can  be  defined  as  an  approach  to  medicine  in  which  medical  decisions  are  tailored  to  the  individual  patient.  In  theory,  personalized  medicine  will  avoid  costly  and  prolonged  trial  and  error  approaches  resulting  in  unwanted  therapeutic  side  effects  or  diminished  treatment  efficacy.  Diagnostically,  personalized  medicine  uses  molecular  tracking  to  signal  risk  of  disease  on  a  genetic  level,  which  may  identify  disease  presence  before  clinical  indications  and  symptoms  appear.  Thus,  personalized  medicine  enhances  the  focus  on  preventive  medicine  at  the  primary,  secondary,  and  tertiary  levels.  Fully  realized,  personalized  medicine  has  the  potential  to  facilitate  early  diagnosis  and/or  prevention  of  disease  and  selection  of  optimal  therapeutic  choices  with  minimal  attendant  side  effects  for  established  disease  states.  The  potential  savings,  from  both  a  financial  and  quality-of-life  perspective,  are  enormous.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1122354736
ER  -